Lazard Asset Management LLC Biotechnology

Lazard Asset Management LLC

$63.4 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
SAGE Sage Therapeutics, Inc.	$516M	$120,000 0.0% of portfolio	13,232	Q2 2025 New
KYMR Kymera Therapeutics, Inc.	$3.31B	$116,000 0.0% of portfolio	2,664	Q2 2025 New
MIRM Mirum Pharmaceuticals, Inc.	$2.68B	$99,000 0.0% of portfolio	1,962	Q2 2025 Reduced 2.0%
CTMX Cytom X Therapeutics, Inc.	$245M	$98,000 0.0% of portfolio	43,316	Q2 2025 Added 5,208.33%
MNKD Mannkind Corp	$1.41B	$93,000 0.0% of portfolio	24,935	Q2 2025 Added 11.79%
INVA Innoviva, Inc.	$1.2B	$92,000 0.0% of portfolio	4,607	Q2 2025 New
ARWR Arrowhead Pharmaceuticals, Inc.	$4.07B	$91,000 0.0% of portfolio	5,771	Q2 2025 New
IBRX Immunity Bio, Inc.	$981M	$91,000 0.0% of portfolio	34,788	Q2 2025 New
DAWN Day One Biopharmaceuticals, Inc.	$544M	$89,000 0.0% of portfolio	13,765	Q2 2025 New
GOSS Gossamer Bio, Inc.	$213M	$82,000 0.0% of portfolio	67,362	Q2 2025 Added 53.93%
TVTX Travere Therapeutics, Inc.	$1.79B	$80,000 0.0% of portfolio	5,461	Q2 2025 Reduced 44.94%
MDGL Madrigal Pharmaceuticals, Inc.	$7.52B	$77,000 0.0% of portfolio	256	Q1 2025 New
ZLAB Zai Lab LTD	$2.81B	$73,000 0.0% of portfolio	2,092	Q2 2025 Reduced 6.23%
TGTX Tg Therapeutics, Inc.	$5.1B	$72,000 0.0% of portfolio	2,027	Q2 2025 Reduced 68.72%
CYTK Cytokinetics Inc	$5.59B	$67,000 0.0% of portfolio	2,055	Q2 2025 Reduced 94.32%
SNDX Syndax Pharmaceuticals Inc	$881M	$66,000 0.0% of portfolio	7,142	Q2 2025 New
ACLX Arcellx, Inc.	$3.75B	$48,000 0.0% of portfolio	735	Q2 2025 Reduced 85.9%
GLUE Monte Rosa Therapeutics, Inc.	$461M	$48,000 0.0% of portfolio	10,857	Q2 2025 Added 42.95%
IPSC Century Therapeutics, Inc.	$33.6M	$35,000 0.0% of portfolio	62,947	Q2 2025 New
FHTX Foghorn Therapeutics Inc.	$168M	$34,000 0.0% of portfolio	7,433	Q2 2025 Reduced 24.21%
KRYS Krystal Biotech, Inc.	$5.03B	$21,000 0.0% of portfolio	155	Q2 2025 Reduced 61.63%
RARE Ultragenyx Pharmaceutical Inc.	$2.41B	$21,000 0.0% of portfolio	588	Q2 2025 Reduced 98.27%
FOLD Amicus Therapeutics, Inc.	$2.37B	$19,000 0.0% of portfolio	3,488	Q2 2025 Reduced 67.75%
ARDX Ardelyx, Inc.	$810M	$18,000 0.0% of portfolio	4,655	Q2 2025 Reduced 71.53%
GERN Geron Corp	$480M	$18,000 0.0% of portfolio	13,123	Q2 2025 Reduced 75.26%
IMTX Immatics N.V.	$835M	$18,000 0.0% of portfolio	3,350	Q2 2025 Reduced 51.02%
KURA Kura Oncology, Inc.	$668M	$18,000 0.0% of portfolio	3,234	Q2 2025 Reduced 72.48%
AGIO Agios Pharmaceuticals, Inc.	$2.34B	$17,000 0.0% of portfolio	534	Q2 2025 Reduced 79.91%
APLS Apellis Pharmaceuticals, Inc.	$2.97B	$17,000 0.0% of portfolio	1,024	Q2 2025 Reduced 71.18%
VCEL Vericel Corp	$1.7B	$17,000 0.0% of portfolio	410	Q2 2025 Reduced 98.62%
XNCR Xencor Inc	$900M	$15,000 0.0% of portfolio	2,001	Q2 2025 Reduced 64.27%
KMPH Kempharm, Inc	$170M	$14,000 0.0% of portfolio	2,959	Q2 2025 New
IOVA Iovance Biotherapeutics, Inc.	$366M	$13,000 0.0% of portfolio	7,744	Q2 2025 Reduced 64.3%
CSBR Champions Oncology, Inc.	$88.2M	$9,000 0.0% of portfolio	1,349	Q2 2025 New
TRDA Entrada Therapeutics, Inc.	$229M	$8,000 0.0% of portfolio	1,256	Q2 2025 Reduced 96.84%
SRPT Sarepta Therapeutics, Inc.	$2.06B	$7,000 0.0% of portfolio	445	Q2 2025 Reduced 90.7%
STRO Sutro Biopharma, Inc.	$60M	$7,000 0.0% of portfolio	10,947	Q2 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.